Lundbeck's Exciting Pipeline Findings Set to Shine at American Academy of Neurology Conference

Lundbeck to Present Promising Data at AAN Annual Meeting

H. Lundbeck A/S, a leading biopharmaceutical company focused on brain health, is preparing to unveil exciting interim results from its innovative PACIFIC trial at the 2025 American Academy of Neurology (AAN) Annual Meeting. This key conference, scheduled to take place in San Diego, promises to highlight the latest advancements in neurological research and treatment options.

The presentation will focus on the open-label extension (OLE) of the Phase 1b/2a PACIFIC clinical trial, which investigates the investigational drug bexicaserin. Aimed at targeting seizures linked to Developmental and Epileptic Encephalopathies (DEEs), this trial represents a significant commitment to addressing unmet medical needs for patients suffering from these severe epilepsy conditions.

Understanding Developmental and Epileptic Encephalopathies (DEEs)

Developmental and Epileptic Encephalopathies are regarded as one of the most challenging forms of epilepsy, characterized by drug-resistant seizures and developmental issues. With over 900 genes involved, DEEs can arise from diverse sources, including acquired, syndromal, and genetic factors. Yet, treatment options remain limited, leaving many patients in search of effective therapies.

During the AAN Annual Meeting, Lundbeck will share critical insights into the six-month results from the PACIFIC trial OLE. This segment of the trial aimed to evaluate the long-term safety, tolerability, and efficacy of bexicaserin in participants who experienced at least six months of therapy. Notably, the OLE interim analysis has shown that bexicaserin maintains a favorable safety and tolerability profile and demonstrates significant reductions in seizure activity among patients upon transitioning from placebo.

Promising Results from the Bexicaserin Trial

The data reveals a remarkable 57.3% decrease in countable motor seizures and a 61.2% reduction in total seizures for participants newly introduced to bexicaserin. Additionally, over half of these newly treated individuals experienced a marked decrease in their seizure counts, further underscoring the potential of bexicaserin in the DEE population.

Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck, expressed enthusiasm about these findings, stating, "The PACIFIC trial and its six-month OLE results demonstrate our commitment to mitigating the challenges faced by patients with DEEs. We are eager to share our findings with the global neuroscience community at AAN and to discuss the potential of bexicaserin to support patients and healthcare providers."

New Analyses on Eptinezumab

In addition to the PACIFIC trial results, Lundbeck will also present new analyses regarding eptinezumab, another important drug in their lineup. Eptinezumab, an FDA-approved preventative treatment for migraines, has shown promise through recent real-world studies. The data will explore meaningful aspects of the medication, such as the frequency of 'good days' experienced by patients and the sustainability of treatment responses. Lundbeck aims to improve expectations surrounding migraine prevention while enhancing awareness of the holistic impact of migraines on everyday life.

Details of the Presentations

Lundbeck's crucial presentations at the 2025 AAN Annual Meeting will feature an oral talk regarding bexicaserin and multiple poster presentations related to eptinezumab. Specifically, the bexicaserin oral presentation is scheduled for April 7, focusing on safety, tolerability, and efficacy findings from the PACIFIC study. Meanwhile, poster presentations will address the significant performance of eptinezumab for chronic migraine patients, demonstrating long-term treatment impacts and quality of life improvements.

About Lundbeck

H. Lundbeck A/S remains dedicated to advancing brain health with a robust portfolio aimed at addressing neurological and psychiatric conditions. With over 70 years in the field, Lundbeck strives to innovate and develop breakthrough treatments to meet the needs of patients across the world. As they prepare for this significant event, Lundbeck's focus continues to be on providing effective solutions for often overlooked and complicated brain disorders, giving hope to countless patients and their families.

For more information about Lundbeck and their initiatives, visit their corporate website or connect via social media platforms.